(Q36038492)

11 August 2017

Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment (English)

1 reference

11 August 2017

1 reference

1 reference

Alessandro Poggi

1

0 references

Maria R. Zocchi

object named as

Maria Raffaella Zocchi

series ordinal

2

0 references

publication date

1 March 2012

1 reference

11 August 2017

1 reference

11 August 2017

1

1 reference

11 August 2017

2

1 reference

11 August 2017

214-216

1 reference

Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377005

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377005

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377005

Effects of imatinib mesylate in osteoblastogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377005

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3377005

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

11 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.4161%2FONCI.1.2.18112

VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.4161%2FONCI.1.2.18112

Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22720246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22720246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Imatinib Mesylate — Uncovering a Fast Track to Adaptive Immunity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22720246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/ONCI.1.2.18112

1 reference

11 August 2017

1 reference

PMC publication ID

3377005

11 August 2017

PubMed publication ID

22720246

1 reference

PMC publication ID

3377005